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Aim: The objective was to investigate the effect of metamizole on renal function in healthy,
salt-depleted volunteers. In addition, the pharmacokinetics of the four major metamizole
metabolites were assessed and correlated with the pharmacodynamic effect using urinary
excretion of the prostacyclin metabolite 6-keto-prostaglandin F1α.
Methods: Fifteen healthy male volunteers were studied in an open-label randomized
controlled parallel group study. Eight subjects received oral metamizole 1,000 mg three
times daily and seven subjects naproxen 500mg twice daily for 7 days. All subjects were
on a low sodium diet (50 mmol sodium/day) starting 1 week prior to dosing until the end of
the study. Glomerular filtration rate was measured using inulin clearance. Urinary excretion
of sodium, potassium, creatinine, 6-keto-prostaglandin F1α, and pharmacokinetic
parameters of naproxen and metamizole metabolites were assessed after the first and
after repeated dosing.
Results: In moderately sodium-depleted healthy subjects, single or multiple dose
metamizole or naproxen did not significantly affect inulin and creatinine clearance or
sodium excretion. Both drugs reduced renal 6-keto-prostaglandin F1α excretion after
single and repeated dosing. The effect started 2 h after intake, persisted for the entire
dosing period and correlated with the concentration-profile of naproxen and the active
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metamizole metabolite 4-methylaminoantipyrine (4-MAA). PKPD modelling indicated less
potent COX-inhibition by 4-MAA (EC50 0.69 ± 0.27 µM) compared with naproxen (EC50
0.034 ± 0.033 µM).
Conclusions: Short term treatment with metamizole or naproxen has no significant effect
on renal function in moderately sodium depleted healthy subjects. At clinically relevant
doses, 4-MAA and naproxen both inhibit COX-mediated renal prostacyclin synthesis.
Keywords: metamizole, 4-methylaminoantipyrine (4-MAA), inulin clearance, urinary sodium excretion, prostacyclin,
6-keto-PGF1α, salt-depleted healthy volunteers
INTRODUCTION
Metamizole (dipyrone) is an effective non-opioid analgesic
and antipyretic drug. It has a favorable gastrointestinal safety
profile, but there is a lack of data on its renal tolerability
compared with classic nonsteroidal anti-inflammatory drugs
(NSAIDs) (Farker et al., 1995; Zapater et al., 2015).
Metamizole is a prodrug (Figure 1) and reaches the
systemic circulation after non-enzymatic cleavage to 4-N-
methylaminoantipyrine (4-MAA), which can be
N-demethylated to 4-aminoantipyrine (4-AA). 4-AA can be
N-formylated to 4-N-formylaminoantipyrine (4-FAA) or
N-acetylated to 4-N-acetylaminoantipyrine (4-AAA).
The mechanism of action of metamizole is not entirely clear.
Inhibition of cyclooxygenase (COX) enzymes by metamizole
metabolites has been demonstrated in ex vivo and in vitro
experiments. However, the reported IC50 values for COX-
inhibition show high variability, ranging from 2.6 μmol/L to
>400 μmol/L and mostly appear to be higher compared to
corresponding IC50 values of non-selective NSAIDs such as
ibuprofen (12–42 μmol/L) or naproxen (0.3–24 μmol/L)
(Campos et al., 1999; Gierse et al., 1999; Hinz et al., 2007;
Pierre et al., 2007; Rogosch et al., 2012). Other proposed
mechanisms of action are stimulation of endogenous
cannabinoid receptors (Rogosch et al., 2012; Crunfli et al.,
2015), involvement of glutamatergic mechanisms, inhibition of
neurokinin-1 receptor or transient receptor potential ankyrin
1(TRPA1) channel mediated responses (Nassini et al., 2015),
inhibition of the protein kinase C-dependent pathway (Siebel
et al., 2004), and involvement of the descending serotonergic and
noradrenergic systems (Gencer et al., 2015).
Regarding safety, the most frequently discussed problem
associated with metamizole is agranulocytosis, a rare but
potentially life-threatening adverse drug reaction (Anonymous,
1986). In addition, metamizole can cause infusion reactions with
profound hypotension, especially after rapid infusion of high
doses (Leone et al., 2005). The most frequent adverse reaction
caused by NSAIDs is gastrointestinal toxicity, ranging from
dyspepsia to severe gastrointestinal ulcerations and bleeding
(CoxibBhala et al., 2013; Scarpignato et al., 2015). Based on
data from animal studies (Sánchez et al., 2002a) and case-
control studies in patients (García Rodríguez and Barreales
Tolosa, 2007; García Rodríguez et al., 2011; de Abajo et al.,
2013; Andrade et al., 2016), metamizole has a more favorable
gastrointestinal safety profile, indicating clinically less relevant
COX-1 inhibition in the gastrointestinal tract compared to
NSAIDs (LaporteCarne et al., 1991; Sánchez et al., 2002b;
Lanas et al., 2003). In addition, NSAIDs and selective
cyclooxygenase-2 (COX-2) inhibitors are associated with an
increased cardiovascular risk, particularly in patients with
preexisting disease (Fosbol et al., 2009; Gislason et al., 2009;
CoxibBhala et al., 2013). For metamizole, so far no increased
cardiovascular risk has been reported (de Abajo et al., 2014); this
however may be due to insufficient study data on the
cardiovascular risk of metamizole compared to NSAIDs.
Themechanism leading to impaired renal perfusion associated
with NSAIDs is well established. Vasodilatory prostaglandins
such as prostacyclin are crucial for maintaining sufficient renal
perfusion in conditions with low intravascular pressure;
inhibition of renal prostaglandin synthesis by NSAIDs can
therefore compromise renal autoregulation. Salt depletion is
assumed to stimulate renal counter-regulations similar to those
induced by hypovolemia and to increase susceptibility of the
kidneys to adverse effects of COX-inhibitors in healthy
individuals (Hörl, 2010). Whether metamizole is a valuable
alternative to NSAIDs for patients with reduced intravascular
volume has not been studied in detail. Only sporadic case reports
of acute kidney injury or acute interstitial nephritis in patients
treated with metamizole are available (Berruti et al., 1998; Abu-
Kishk et al., 2010; Hassan et al., 2011).
Considering the increasing use of metamizole in many
countries (Stammschulte et al., 2015) and the lack of study
data on its effect on renal function, the primary aim of this
study was to examine the effect of metamizole compared with the
non-specific COX-inhibitor naproxen on renal function in
healthy, salt-depleted, male volunteers. Renal function was
assessed by measuring glomerular filtration using inulin
clearance as well as measuring urinary excretion of sodium,
potassium, creatinine and the stable prostacyclin metabolite 6-
keto-prostaglandin F1α (6-keto-PGF1α). A secondary aim was to
obtain pharmacokinetic data for the four major metamizole




Metamizole was administered as Novalgin® 500 mg
tablets (Sanofi-Aventis Suisse SA, Vernier, Switzerland) and
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naproxen as Naproxen-Mepha® Lactabs 500 mg
(Mepha Pharma AG, Basel, Switzerland). Inulin (Inutest®
25% ampules) was from Fresenius Medical Care AG
(Oberdorf, Switzerland, manufactured by Fresenius Kabi
Austria GmbH, Linz, Austria). D-Glucose/D-Fructose Test-
Combination was from R-Biopharm AG (Darmstadt,
Germany), glucose-oxidase from Aspergillus niger and
invertase from baker’s yeast (S. cerevisiae) were from
Sigma-Aldrich (Buchs, Switzerland). Citric acid, sodium
citrate, and hydrogen peroxide 30% were also purchased
from Sigma-Aldrich (Buchs, Switzerland).
Gradient grade water, methanol, isopropanol and formic acid
of analysis grade (98–100% purity) for liquid chromatography
were obtained from Merck (Darmstadt, Germany). Chloroform
was from Carl Roth (Karlsruhe, Germany) and O-(2,3,4,5,6-
pentafluorobenzyl)hydroxylamine hydrochloride (PFBHA) was
from Sigma-Aldrich (Buchs, Switzerland). All reference
compounds and internal standards for naproxen and
metamizole quantification were products of Toronto Research
Chemicals (Toronto, Canada). 6-keto PGF1α, 6-keto PGF1α-d4,
and 2,3-dinor-6-keto-PGF1-α were obtained from Cayman
Chemicals (Ann Arbor, Michigan, United States). Stock
solutions of naproxen (10 mg/ml), 6-Keto PGF1α-d4 (1 mg/
ml) and the metamizole metabolites 4-methylaminoantipyrine
(4-MAA; 10 mg/ml), 4-aminoantipyrine (4-AA; 5 mg/ml), 4-
formylaminoantipyrine (4-FAA; 5 mg/ml), and 4-
acetylaminoantipyrine (4-AAA; 5 mg/ml) were prepared in
dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis,
United States). The internal standards 2,3-Dinor 6-Keto
PGF1α-d9, 4-MAA-d3, 4-AA-d3, and 4-AAA-d3, and
naproxen-d3 were dissolved in DMSO to a final concentration
of 1 mg/ml.
Study Protocol
This single-center, randomized, open-label, parallel-group
study in healthy, male subjects was approved by the local
ethics committee (Ethikkommission beider Basel, EKBB 264/
13) and the Swiss Agency for Therapeutic Products
(Swissmedic Bern, protocol number 2013DR1187). The
study was conducted in the phase I research unit at the
University Hospital Basel, Switzerland and was registered at
ClinicalTrials.gov (NCT01995006). Before inclusion into the
study, we obtained written informed consent and performed a
physical examination including routine laboratory tests of
each subject. Healthy male subjects, without history of
gastrointestinal disease or intolerance to NSAIDs were
eligible (list with complete inclusion and exclusion criteria
provided as Supplementary Table S1). According to the
protocol, 16 subjects were planned to be included with
subsequent 1:1 randomization according to a pre-specified
randomization list into two treatment groups. One group
was to be treated with a single dose of 1,000 mg metamizole
on day 1 followed by 1000 mg metamizole three times daily
from day 2 to day 7, the other group with a single dose of
500 mg naproxen on day 1 followed by 500 mg naproxen twice
daily from day 2 to day 7 days. One week before the first study
day, all subjects were started on a low sodium diet containing
approximately 50 mmol sodium per day (Muther et al., 1981;
Rossat et al., 1999). The diet was maintained during the whole
study period (i.e., until the last blood sampling on day 8).
Lunch and dinner with reduced sodium content were provided
at the University Hospital Basel during the whole study period.
For breakfast and snacks, we provided written dietary
instructions. Dietary sodium intake was monitored by
measuring urinary sodium excretion in 24 h urine with
sample collection starting on days -4, 1, and 7 to assess
FIGURE 1 |Metabolism of metamizole. The prodrug metamizole is non-
enzymatically cleaved to 4-N-methylaminoantipyrine (4-MAA), which is
N-demethylated to 4-aminoantipyrine (4-AA). 4-AA can be N-formylated to 4-
N-formylaminoantipyrine (4-FAA) or N-acetylated to 4-N-
acetylaminoantipyrine (4-AAA).
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compliance with the low sodium diet (Supplementary Figure
S1, Table S2). Plasma samples for the pharmacokinetic
evaluation were drawn before, and 1, 2, 3, 4, 5, 8, 12, and
24 h after drug administration. Starting on day 2, the study
drugs were given at the regular dosing interval until day 7. On
day 7, the PK measurements were repeated at the same time-
points as on day 1.
Measurement of Inulin Clearance
On day 1, after an overnight fast, a venous catheter was placed on
each forearm. After the collection of baseline plasma samples, we
started an inulin infusion at 125 mg/min for 20 min followed by
28 mg/min for 400 min according to the instructions of the
manufacturer. After an equilibration period of 1 hour, we
collected a urine sample to measure baseline inulin
concentrations (t-1 to t0), before subjects ingested a single dose
of either 1,000 mg metamizole or 500 mg naproxen (t0). We
continued to collect hourly urine and plasma samples for
inulin concentration measurements for the next 5 hours (t1 -
t5). Inulin clearance was calculated according the following
formula:






where inulinurine is the inulin concentration in urine, volumeurine
the volume of urine, inulinplasma the inulin concentration in
plasma, time the collecting period, and bs the body surface. To
ensure a minimal urine flow of 2–3 ml/min (according to the
manufacturer’s recommendation), we instructed the study
participants to drink 700 ml of water within the first 30 min
after the start of the inulin infusion, followed by additional 300 ml
of water per hour until the end of the inulin infusion (t5).
Inulin concentrations in plasma and urine were measured
using an enzymatic method without deproteinization as
described previously (Kuehnle et al., 1992). Standard curves
were linear in plasma (mean r2  0.9994, n  17) and in urine
(mean r2  0.9991, n  12). For different concentration
calibrators, the coefficients of variation for repetitive
measurements were 6.2–9.6% for plasma and 9.6–11.2%
for urine.
Creatinine Renal Excretion and Clearance
We determined the urinary creatinine excretion by multiplying
the urine volume by the corresponding urine creatinine
concentration. Division of the urinary creatinine excretion per
time by the corresponding creatinine serum concentration
yielded the creatinine clearance after normalization to 1.73 m2
body surface.
Quantification of Sodium and Potassium
Excretion in Urine
We measured sodium and potassium excretion in aliquots of
hourly urine collections. Potassium concentrations in urine were
analyzed using ion-specific electrodes at the central laboratory of
the University Hospital Basel. Sodium concentrations in urine
were analyzed at the environmental health and safety laboratory,
Office of Environment and Energy of the Canton of Basel,
Switzerland, using an inductively coupled plasma mass
spectrometry (ICP-MS) method (DIN EN ISO 17294-2:2005-
02) with a detection limit of 0.05 mg/L.
Quantification of Naproxen and Metamizole
Metabolites
Concentrations of naproxen and metamizole metabolites were
measured on a Shimadzu HPLC system (Kyoto, Japan) coupled to
an API 4000 tandem mass spectrometer (AB Sciex,
Massachusetts, United States). The HPLC system consisted of
two LC-20AD pumps, two LC-20AD XR pumps, a CTO-20AC
column oven, a DGU-20A5 degassing unit, a CBM-20A
controller, and a CTC HTS PAL autosampler (Zwingen,
Switzerland). The LC-MS/MS system was operated using
Analyst software version 1.6.1 (AB Sciex, MA, United States).
4-MAA, 4-AA, 4-FAA, and 4-AAA were separated on a
pentafluorophenyl phase column (Luna 3 µ PFP 50 mm ×
2.0 mm, Phenomenex, CA, United States) using water (A) and
methanol (B), both supplemented with 0.1% (v/v) formic acid as
mobile phases. The following mobile phase gradient program was
used: 0–0.25 min; 2% mobile B, 0.25–3.5 min; 2–55% mobile B,
3.51–4.5; 95% mobile B, 4.51–5.0 min; 2% mobile B. The
retention times of 4-MAA, 4-AA, 4-FAA and 4-AAA were
1.62, 1.74, 2.43, and 2.5 min, respectively. For
chromatographic separation the column was kept at 43°C. All
analytes were detected in positive mode using electrospray
ionization.
Naproxen was eluted on a reversed phase core-shell C18
column (Kinetex 2.6 µm, 50 mm × 2.1 mm; Phenomenex, CA,
United States). Similar mobile phases were used as for the
metamizole analysis. The HPLC gradient program was:
0–0.25 min; 40% mobile B, 0.25–1 min; 40–95% mobile B,
1–2 min; 95% mobile B, 2.01–2.25 min; 40% mobile B.
Naproxen eluted after 1.3 min. Naproxen and naproxen-d3
were detected in negative ionization mode. General settings of
the mass spectrometer were similar to the ones used for the
analysis of metamizole except the ion spray voltage which was set
to −4500 V.
Calibration lines were prepared in drug free blank human
plasma. Analyte stock solutions were serially diluted with DMSO
and each dilution was mixed with blank plasma at a ratio of 1:100.
Calibration ranges which included 10 or 11 calibrators were
established from 25–50′000 ng/ml for naproxen, from
50–50′000 ng/ml for 4-MAA, from 25–5,000 ng/ml for 4-FAA,
and from 5–5,000 ng/ml for 4-AA and 4-AAA. A correlation
coefficient (R2) of at least 0.99 was required. Quality control
samples were prepared at low, medium, and high concentration
levels. A mean accuracy of 85–115% (80–120% at the lower limit
of quantification (LLOQ)) and a precision of 15% (LLOQ: 20%)
was accepted in our study.
Plasma aliquots of 50 µl were precipitated with 500 µl
methanol containing the internal standards (4-AA-d3: 10 ng/
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ml, 4-AAA-d3: 50 ng/ml, 4-MAA-d3: 25 ng/ml, naproxen-d3:
500 ng/ml). Samples were mixed for 1 min and centrifuged at
3,220 g for 30 min (Eppendorf 5810R, Hamburg, Germany). 2 µl
supernatant were injected into the LC-MS/MS system.
Quantification of Urinary 6-Keto-PGF1-α
Concentrations of 6-keto-PGF1- α in urine were measured on a
UPLC system from Shimadzu connected to an AB Sciex API 5500
tandem mass spectrometer. The UPLC system had the same
configuration as the HPLC system used for naproxen and
metamizole except that four 30-AD pumps and a SIL-30AC
autosampler were used.
Derivatization of the ketone group of 6-keto PGF1α using
PFBHA resulted in the formation of two isomers. These isomers
were separated on a Kinetex C18 column (2.6 µm, 50 mm ×
2.1 mm, Phenomenex, CA, United States). Mobile phase A was a
5 mM ammonium bicarbonate (Sigma-Aldrich, MO,
United States) solution in water, for mobile phase B
isopropanol was used. The introduced samples (50 µl) were
pre-column diluted via a T-union during the first 0.5 min of
each run with mobile phase A. The following mobile phase B
gradient program was used: 0–11 min; 2–23%, 11–12 min;
23–95%, 12–13 min; 95%, 13–13.5 min; 2%. 2,3-dinor-6-keto-
PGF1α eluted after 9.4 min and the two PFBHA-6-keto PGF1α
isomers, had a retention time of 10.0 and 10.4 min, respectively.
All analytes were detected in negative mode using atmospheric
pressure chemical ionization. The applied mass transitions and
compound specific parameters are shown in Supplementary
Table S3.
Calibration lines with 10 calibrators from 10 to 2,500 pg/ml
were prepared by spiking blank human urine with 6-keto PGF1α-
d4 (in DMSO) at a ratio of 1:1,000. Quality control samples were
prepared at low (75 pg/ml), medium (250 pg/ml), and high
(750 pg/ml) concentration levels. We applied a modified
liquid-liquid extraction technique as described by Sterz et al.
(Sterz et al., 2012). Aliquots of 2 ml urine were used for analysis.
Before extraction, 20 μl of acetic acid were added to each sample,
followed by 8 ml of the IS (2,3-dinor-6-keto-PGF1α) in a
methanol-chloroform (2:1 v/v) mixture. The samples were
mixed during half an hour and incubated for another half an
hour at room temperature. After adding chloroform and water
(2.5 ml each), the samples were mixed for 10 min and afterwards
centrifuged for 10 min at 800 g. The chloroform phase was
evaporated under a gentle stream of nitrogen at 40°C with a
Turbo Vap LV (Caliper Life Science, MA, United States). The
residue was dissolved in a 200 μl isopropanol-water-PFBHA
solution (4:5:1, v/v) and incubated for 30 min at 60°C for
derivatization (Blatnik and Steenwyk, 2010). 50 µl was injected
into the LC-MS/MS system. Quantified concentrations of 6-keto-
PGF1α were normalized to the creatinine content of the urine
samples to compensate for differences in urine dilution. Values
below the LLOQ of the analytical method were set to the
LLOQ value.
Pharmacokinetic Analysis
Plasma concentration data were analyzed using non-
compartmental methods. Peak plasma concentrations (Cmax)
and time to reach Cmax (tmax) were directly obtained from
observed concentration-time data. The terminal elimination
rate constant (λz) was obtained by log-linear regression using
at least three data points in the elimination phase. The area under
the concentration-time curve (AUC) from zero to infinity after
dosing (AUC0-inf_obs) was estimated using the linear trapezoidal
method and was extrapolated to infinity based on the last
observed or predicted concentration. Partial area under
concentration-time curve from 0 to 5 h (AUC0-5h) was
calculated for comparison of the two treatment days. The
terminal elimination half-life was calculated using λz.
Calculations were done using the PK Solver add-in (version
2.0) for Microsoft Excel (Zhang et al., 2010).
Pharmacokinetic and Pharmacodynamic
Modeling
For the PKPD model, pharmacokinetics and pharmacodynamics
of metamizole and naproxen were analyzed by compartmental
methods. The respective differential equations were solved using
the generalized least squares algorithm of the ADAPT 5 software
(Biomedical Simulation Resource, University of Southern
California, Los Angeles, CA, United States). The
compartmental structures of the PKPD models used for
metamizole and naproxen are shown in Figure 2.
The effect compartment was assumed to be linked to the X1
compartment (4-MAA) for metamizole and the central
compartment (Vc) for naproxen. The inhibitory effect on
urinary 6-ketoPGF1a excretion was then related to the
concentrations of the drugs in the effect compartment by the
sigmoid Hill-equation:




Where E0 denotes the initial effect, Emax the maximal effect, EC50
the concentration at half-maximal effect in the effect
compartment and N the sigmoidicity coefficient. In both
models, central compartment and effect compartment are
linked with a first-order equilibration rate constant k1e while
ke0 denotes the elimination rate constant from the effect
compartment.
Statistical Analysis
No statistical hypothesis was set for this exploratory study. The
sample size was chosen based on practical considerations. The
random list was obtained using an open source random
generator on Random.org. Statistical analyses were
performed using GraphPad PRISM (Version 6, La Jolla,
California, United States). For variables with normally
distributed numerical values, arithmetic mean and standard
deviations were calculated. For non-normally distributed
variables, median and range were used. Urinary sodium
excretion values were tested for between group differences
using 2-way ANOVA with Holm-Šidak correction for multiple
comparisons. Calculated inulin clearance values were
parameterized by calculating areas under effect curve
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(AUEC) from time 0–5 h. AUECs between the metamizole
and the naproxen group were statistically compared using a
Mann-Whitney-U-test, whereas AUECs within a treatment
group, but of different study days were tested using a Wilcoxon
signed rank test. The course within a treatment group on a
single study day was evaluated using a Friedman-test.
Statistical differences were considered as significant when
p ≤ 0.05.
RESULTS
Fifteen subjects completed the study. Demographic data
and blood pressure values are shown in Supplementary
Table S4. Eight subjects received metamizole, 7 subjects
received naproxen. Two subjects allocated to naproxen
dropped out before administration of the study drug. One
subject withdrew consent, and the other subject developed an
adverse reaction to inulin (nausea and vomiting, CTCAE grade
1). One of the two replacement subjects developed
bronchospasm (CTCAE grade 3) after the start of the inulin
infusion and was not replaced.
Median urinary sodium excretion was less than 60–80 mmol/
day on day 3 and day 2 but exceeded the target range at the end of
the treatment period (Table 1).
Metamizole and naproxen had no significant effect on inulin
or creatinine clearance both at day 1 and day 7 (Figures 3A–D).
Creatinine excretion, for the completeness of bladder emptying
during the urine collection periods, was not influenced by
metamizole or naproxen and showed no significant differences
among the collected urine fractions of the treatment groups
(Supplementary Table S5).
FIGURE 2 | Compartmental structures of the PKPD models for metamizole metabolites (A) and naproxen (B). Dosing of drugs was assumed to the gut
compartment (X0). Concentration in this compartment was related to the central compartments VC and X1 by a first-order rate constant (ka) that represented both
dissolution and absorption from the gut into systemic circulation (naproxen) and in addition the formation of 4-MMA from metamizole, respectively. For metamizole the
intercompartmental rate constants k12, k21, k14, k23, k24 represent the first-order interconversion rate constants from one metabolite species into another. The rate
constants k10, k20, k30, k40, are elimination rate constants from compartments X1 (4-MAA), X2 (4-AA), X3 (4-AAA), and X4 (4-FAA), respectively. The peripheral
compartment for naproxen is denoted by 2. In both models the effect compartment was linked to the central compartment (X1 or Vc) of the active metabolite 4-N-
methylaminoantipyrine (4-MAA) or naproxen by the intercompartmental rate constant k1e and keo was used as elimination rate constant from the effect compartment.
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Both drugs had only minimal and clinically not relevant effects
on urinary sodium and potassium excretion (Figures 3E–H).
Naproxen and metamizole both decreased urinary 6-keto-
PGF1α excretion. On day 1, before administration of the first
dose, the urinary 6-keto-PGF1α concentrations in the
baseline samples were higher than the lower limit of
quantification of the analytical method for all subjects. Two
hours after a single dose of metamizole or naproxen, the 6-
keto-PGF1α concentrations started to decrease and remained
low up to 5 h in most of the subjects (Figure 4A). At steady
state (day 7), the trough value before administration of
the morning dose was lower than the baseline value on
day 1, indicating a long-lasting effect of both treatments on
renal 6-keto-PGF1α excretion (Figure 4B). Concentrations
of 6-keto-PGF1α decreased to levels below the limit of
quantification (LLOQ, 8 pg/ml) after ingestion of
metamizole in all subjects on day 1 and in 7 of 8 subjects
on day 7. After naproxen this was the case for 5 of 7 subjects on
day 1 and for all 7 subjects on day 7.
The concentration-time profiles of the four main metamizole
metabolites after single and multiple oral doses are shown in
Figure 5 and the corresponding pharmacokinetic parameters are
listed in Table 2. 4-MAA reached the highest plasma
concentrations of all metabolites, both after single and
multiple dose treatment. After single dose, the Cmax values of
the other metabolites 4-AA, 4-AAA and 4-FAA were 10–20 times
lower compared with 4-MAA.
The concentration-time profiles of naproxen are shown in
Supplementary Figure S2 and the corresponding
pharmacokinetic data are listed in Supplementary Table S6.
The results of the pharmacokinetic and pharmacodynamic
models of metamizole and naproxen are given in Table 3 and
Figure 6 and individual model fits are shown in
Supplementary Materials. The plasma concentration-time
curve of the primary metamizole metabolite 4-MAA and the
effect of 4-MAA on the urinary excretion of 6-keto-PGF1α was
well described by the model. The pharmacokinetics of the
other three metamizole metabolites (4-AA, 4-FAA and 4-
AAA) showed a lower agreement with the non-
compartmental analysis. For naproxen, data from one
subject led to unrealistic model output and had to be
excluded, the averaged results of the remaining six subjects
matched well with the non-compartmental analysis. Overall,
the PKPD models indicated a significantly (p  0.038) lower
EC50 (0.034 vs 0.69 µM) and an approximately two-fold higher
Emax (134 vs 61 pg 6-ketoPGF1α/mg creatinine) for naproxen
compared with metamizole.
DISCUSSION
In this study we investigated the effect of single and repeated
doses of metamizole and naproxen on renal function in
moderately salt depleted healthy human volunteers and we
analysed the pharmacokinetics of the four main metamizole
metabolites.
Under our experimental conditions, metamizole and
naproxen had no clinically relevant effect on inulin or
creatinine clearance.
Compared to the creatine clearance, the average inulin
clearance in our study was approximately 20 ml/min lower.
Creatinine clearances have been reported to exceed
corresponding inulin clearances, possibly due to additional
tubular creatinine secretion. In one study, the ratio of
measured creatinine clearance to inulin clearance varied
between 1.1 and 2.3, which is in agreement with our findings
(van Acker et al., 1992). Incomplete emptying of the bladder or
incomplete distribution of inulin after the 1 h equilibration
period, causing variations in plasma concentration and renal
excretion could be possible reasons for the low baseline values we
observed. Since the formula to calculate inulin clearance relies on
stable plasma levels over the entire observation period,
insufficient equilibration is a possible cause for bias.
The lacking effect of naproxen on inulin clearance (and,
therefore, GFR) was unexpected. In a previous clinical study
with a comparable study design (except for a single dose
furosemide pre-treatment), there was also no decrease in GFR
after single dose of naproxen (Rossat et al., 1999). However, after
repeated naproxen doses, a decrease in GFR of approximately
20% was observed (Rossat et al., 1999). The observation that our
study subjects had a higher 24 h sodium excretion at the end
compared to the start of the study, suggesting insufficient Na+
depletion, is a possible explanation for the lacking effect of
naproxen on the GFR at day 7. Since our positive control
naproxen did not significantly decrease inulin clearance, it is
difficult to evaluate the effect of metamizole on GFR. At least
under the conditions of our study, even repeated doses of
metamizole did not decrease the inulin clearance. In 1995,
Farker and colleagues investigated the influence of metamizole
and diclofenac on glomerular filtration and renal perfusion in
healthy male subjects by measuring the creatinine and inulin
clearances and the clearance of para-aminohippurate (PAH)
(Farker et al., 1995). In their study, neither metamizole, nor
diclofenac at therapeutic doses over 3 days had a significant effect
on GFR or renal plasma flow. Since diclofenac did not have an
effect on these parameters also in other studies (Kinn et al., 1989;
Fredman et al., 1999; Dilger et al., 2002; Farker et al., 2002;
Whelton et al., 2006), it appears to be difficult to demonstrate the
consequences of COX inhibition on renal function in healthy
volunteers. Results from studies with naproxen were not
consistent, with some studies showing a decrease in inulin
clearance but not of the estimated creatinine clearance
(Kamper et al., 1986; Eriksson et al., 1990; Huledal et al., 2005).
After a single dose, both metamizole and naproxen tended to
increase renal sodium excretion, possibly due to the water load
given to the study subjects (Anastasio et al., 2001; Wouda et al.,
TABLE 1 | Urinary sodium excretion in 24 h urine samples.
Sodium excretion [mmol/day]
Metamizole (n = 8) Naproxen (n = 7)
run-in period (day-4 to day-3) 52 (29–64) 43 (29–67)
start of treatment (day 1 to day 2) 53 (26–82) 52 (34–132)
end of treatment (day 7 to day 8) 85 (31–127) 104 (85–121)
Data are given as median (range).
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FIGURE 3 | Effects on renal inulin and creatinine clearance and sodium and potassium excretion. The renal clearances of inulin (reflecting GFR) and creatinine after a
single oral dose of 1 g metamizole and 500 mg naproxen (day 1, left panels) and after repetitive dosing at day 7 (right panels) are displayed in Figures 4A–D,
respectively. Renal sodium excretion (Figures 4E,F) and potassium excretion (Figures 4G,H) as the difference to baseline excretion (time interval 08:00 to 09:00). The
basal sodium excretion (mean ± SEM) was 40 ± 9 µmol/min and the basal potassium excretion 53 ± 12 µmol/min. Data are presented as mean values ±SEM. *p <
0.05 naproxen vs metamizole of the same time interval. There were no significant differences with baseline values within the different treatment groups.
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2019). After repeated dosing (and with the same oral water load as
on day 1), sodium excretion decreased in the subjects treated with
naproxen and increased in those treated with metamizole
compared to baseline (Figures 3E,F). However, with the
exception of the 3-h time-point, the differences were not
statistically significant and can be considered as clinically not
relevant. In a previous study (Rossat et al., 1999), decreased
urinary sodium excretion had already been observed after a
single dose of naproxen, possibly due to the more pronounced
salt depletion (urinary sodium excretion 26–37 mmol/day vs
43–52 mmol/day) compared to our study.
The observed pharmacokinetic data of metamizole are in
line with previously published values. The main metabolite 4-
MAA showed a median half-life of 3.7 h, which is comparable
to published values (Levy et al., 1995; Novalgin, 2015). The
observed half-life for the other active metabolite 4-AA was
comparable to values reported for slow N-acetylators (5.5 h, vs
3.8 h for rapid acetylators (Novalgin, 2015)). The Cmax of 4-
MAA observed in the current study was in the higher range
(14.9 mg/L in current study compared to 9.7–17.3 mg/L) and
the AUC0-inf was slightly above previously reported values
(107 mg/L x h in the current study compared to 64.5–95.1 mg/
L x h (Levy et al., 1995)). The ratios of Cmax and AUC0-5h after
repeated dosing compared with values after single doses
indicated 1.4 and 3.2-fold accumulation of the active
metabolites 4-MAA and 4-AA, respectively. This is
compatible with the half-lives of the two metabolites in
relation to the dosing interval of 8 h 4-MAA reached
approximately 7 to 10-fold higher values for Cmax and AUC
compared to 4-AA and it is therefore primarily responsible for
the analgesic effect of metamizole both after single and
repeated dosing. Regarding toxicity, whose mechanisms are
currently not well established, the other metabolites may also
contribute.
After single and multiple dose treatment, metamizole and
naproxen both reduced renal 6-keto-PGF1α excretion, indicating
COX-inhibition by both drugs (Figure 4). The reduction of the
urinary 6-keto-PGF1α excretion started 2 h after drug
administration, which corresponds well with the Tmax of
naproxen and the active metamizole metabolite 4-MAA, but
not with the time course of the other metamizole metabolites.
The effect lasted for the whole observation period except for a few
subjects, who showed a moderate increase of 6-keto-PGF1α
FIGURE 4 | Urinary 6-keto-PGF1α excretion. Excretion of urinary 6-
keto-PGF1αmeasured after a single oral dose of 1,000 mg metamizole (A) or
500 mg naproxen (B) on day 1 and after multiple daily dosing on day 7. Data
are presented as individual data (filled circles) normalized to urinary
creatinine content and median values (horizontal lines).
FIGURE 5 | Pharmacokinetic profiles of metamizole metabolites. Plasma
concentration vs time profiles of the four metamizole metabolites 4-MAA, 4-
AA, 4-FAA and 4-AAA in healthy volunteers (n  8) following a single oral dose
of 1,000 mg metamizole (A) and after 7 days of continuous intake of
1,000 mg metamizole three times per day (B). In panel (B) only data from the
first dose interval (0–5 h) is shown. Data are presented as mean and SD.
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excretion towards the end of the observation period. Before
ingestion of the morning dose on day 7, 6-keto-PGF1α
excretion was lower compared to the baseline on day 1 in
both groups, indicating persistent COX-inhibition 12 h after
intake of the previous drug dose. As concentrations below the
LLOQ of the bioanalytical method were set to the LLOQ value,
the observed effect size is a conservative estimate of the true effect.
For most subjects, the urine creatinine concentrations in the
2–5 h fractions were comparable to the baseline fraction,
indicating that the observed decrease of 6-keto-PGF1α
concentrations after metamizole or naproxen was not caused
by urine dilution.
According to the EC50 values obtained from the PKPDmodels,
4-MAA was a less potent (i.e., higher EC50 value) inhibitor of
prostacyclin formation compared with naproxen, which had an
approx. 20-fold lower EC50. Although plasma concentrations of
4-MAA were much higher after therapeutic doses of metamizole
than those of naproxen, they both were well above the
corresponding EC50 values obtained by the PKPD models,
which is compatible with the comparable effect sizes observed
for the two drugs. As the concentrations of 6-keto-PGF1α
decreased to levels below the quantification limit of the
analytical method in most of the subjects within a few hours
after dosing, the lower plateau (or maximal effect) could not be
quantified precisely, but given the low LLOQ of the method, the
possible error is small. The differences in observed maximal effect
(Emax  efficacy) thus primarily come from differences in the
baseline concentrations of 6-keto-PGF1α in the two small groups
and, overall, the two drugs appear to have a roughly comparable
effect size.
Both PKPD models assume that the effect in the effect
compartment is linked to the concentration of the active
substance in the central compartment (Vc). In the case of
naproxen, the active substance is naproxen itself; in the case of
metamizole, it is the metabolite 4MAA. As PK data of the other
metamizole metabolites (4AA, 4AAA, 4FAA) was available, the
PKPD model used for naproxen was expanded to includes these
metabolites. However, the changes only concern the peripheral
compartment and the other metamizole metabolites are not
needed to explain the effect of metamizole.
Despite the reduction of 6-keto-PGF1α excretion in both
groups, we did not observe a reduction in the glomerular
filtration rate. The most likely explanation is that our study
subjects were not sufficiently sodium depleted to make
glomerular perfusion dependent on renal synthesis of
vasodilatory prostaglandins such as prostacyclin. A decrease in
renal prostaglandin excretion after metamizole intake has been
TABLE 2 | Pharmacokinetic parameters after a single oral dose of 1,000 mg metamizole (n  8) on day 1 and after multiple doses (1,000 mg TID) on day 7.
4-MAA 4-AA 4-AAA 4-FAA
Day 1
Cmax [mg/L] 14.9 (11.9–18.5) 1.2 (0.6–2.5) 1.6 (0.8–2.5) 1.9 (1.4–2.3)
Tmax [h] 1 (1–2) 5 (3–5) 12 (8–24) 8 (5–12)
AUC0-24h [mg/L x h] 105 (67–128) 15 (7–31) 30 (15–471) 34 (27–40)
AUC0-inf [mg/L x h] 107 (67–129) 16 (7–39) - 65 (45–75)
AUC0-5h [mg/L x h] 58 (48–70) 4.3 (2.3–8.8) 2.9 (1.0–5.2) 5.9 (4.2–7.6)
T1/2 [h] 3.7 (2.8–4.4) 5.8 (4.0–12.4) - 16.0 (8.9–27)
Day 7
Cmax [mg/L] 21.2 (15.7–24.8) 3.0 (1.1–8.9) 8.3 (2.0–11.3) 3.5 (2.0–4.8)
Cmax ratio MD/SD 1.35 2.22 4.85 1.77
AUC0-5h [mg/L x h] 82.6 (55.1–106) 13.9 (4.8–42.4) 39.1 (9.2–53.9) 16.3 (8.7–22.0)
AUC0-5h ratio MD/SD 1.42 3.24 13.35 2.77
Data are given asmedian and ranges. AUC0-24h, partial area under concentration-time curve from 0 to 24 h; AUC0-5h, partial area under concentration-time curve from 0 to 5 h (adapted to
dosing interval); Cmax, maximum plasma concentration; MD, multiple dose; SD, single dose; T1/2, half-life; TID, three times per day; Tmax, time to maximum plasma concentration.
TABLE 3 | Parameters of the pharmacokinetic and pharmacodynamic models for
metamizole and naproxen. The model is described in the methods section.
Values are presented as mean ± SEM.
Metamizole (n = 8) Naproxen (n = 7)
Ka (1/h) 2.528 ± 0.403 Ka (1/h) 0.538 ± 0.76
V1/F (L) 71.2 ± 3.0 Vc/F (L) 3.27 ± 1.12
k12 (1/h) 0.030 ± 0.010 K10 (1/h) 0.185 ± 0.096
k14 (1/h) 0.006 ± 0.002 k12 (1/h) 1.334 ± 0.677
k10 (1/h) 0.178 ± 0.025 k21 (1/h) 0.213 ± 0.073
V2/F (L) 35.6 ± 13.9 V2/F (L) 16.8 ± 5.58a
k23 (1/h) 0.552 ± 0.162 k1e (1/h) 0.009 ± 0.005
k24 (1/h) 0.033 ± 0.025 keo (1/h) 2.275 ± 0.945
k20 (1/h) 0.008 ± 0.007
V3/F (L) 55.1 ± 19.7
k30 (1/h) 0.074 ± 0.008
V4/F (L) 11.5 ± 5.1
k40 (1/h) 0.567 ± 0.476
ke0 (1/h) 0.012 ± 0.004
T1/2 K01 (h) 0.36 ± 0.09 α (1/h) 1.708 ± 0.741
T1/2 4-MAA (h) 3.43 ± 0.29 β (1/h) 0.028 ± 0.004a
T1/2 4-AA (h) 2.39 ± 0.71 T1/2, Ka (h) 2.14 ± 0.63
T1/2 4-AAA (h) 10.33 ± 1.25 T1/2, α (h) 1.00 ± 0.01
T1/2 4-FAA (h) 6.95 ± 1.13 T1/2, β (h) 22.10 ± 1.32a
EC50 (µM) 0.69 ± 0.27 EC50 (µM) 0.034 ± 0.033
N 18.4 ± 9.0 N 7.2 ± 3.9
E0
b 101.6 ± 11.9 E0 167.16 ± 33.68
Emax
b 61.3 ± 16.3 Emax 133.56 ± 37.43
Ka, absorption rate constant; V1, Vc, volume of central compartments; V/F, apparent
volume of distribution; α, distribution rate constant; β, terminal elimination rate constant,
k1e, k12, k14, k23, k24, intercompartmental rate constants; k10, k20, k30, k40, elimination rate
constants; keo, equilibration rate constant between central compartment and effect
compartment; T1/2, half-life; EC50, concentration of half-maximal effect; Emax, maximal
effect; E0, initial effect; N, sigmoidicity coefficient of sigmoid Hill-equation.
an  6 (1 subject excluded due to unrealistic model output).
bUnits for E0 and Emax are pg/mg creatinine (excretion of 6-ketoPGF1α normalized to
creatinine content in urine).
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described in previous studies with healthy volunteers
(Rosenkranz et al., 1992) and in patients with liver cirrhosis
with or without ascites (Zapater et al., 2015). In these patients,
metamizole did not reduce renal function when used for a short
time period of 72 h. Since patients with liver cirrhosis are at
increased risk for renal failure after inhibition of prostaglandin
synthesis (Imani et al., 2014; Elia et al., 2015), these results
support better renal tolerability of metamizole compared to
conventional NSAIDs in patients with reduced intravascular
volume. Production of vasodilatory prostacyclin is an
important counter-regulatory mechanism to maintain renal
perfusion in states of intravascular volume contraction. As
synthesis of prostacyclin seems to be similarly affected by
metamizole as by naproxen, other mechanisms may to be
responsible for the better renal tolerability of metamizole
compared to classic NSAIDs observed in clinical practice. One
possible mechanism could be COX-independent direct smooth
muscle relaxant effects of metamizole which have previously been
described in various animal models (Ergün et al., 1999; Ergün
et al., 2000; Valenzuela et al., 2005; Gulmez et al., 2006; Gülmez
et al., 2008; Silav et al., 2017).
A limitation of our study is the lack of the positive control
naproxen to reduce inulin clearance, most likely due to
insufficient sodium depletion of our study subjects at the end
of the repeated dosing period. Further limitations are the lack of a
placebo group which would have helped to differentiate the effect
of the water load on inulin clearance and renal sodium excretion
and the uncertainties in the model estimates of individual
pharmacodynamic effects. In addition, we did not assess the
renal blood flow, which might have shown an effect of naproxen.
In conclusion, metamizole had a comparable effect on renal
excretion of the prostacyclin metabolite 6-keto-PGF1α and thus
seems to inhibit renal prostacyclin synthesis to a similar degree as
the non-specific NSAID naproxen. Despite reducing renal 6-
keto-PGF1α excretion, none of the drugs had a significant effect
on glomerular filtration rate or sodium and potassium excretion
in healthy, moderately sodium-depleted subjects. Possible
mechanisms for the better renal tolerability of metamizole
compared to conventional NSAIDs observed in clinical
practice such as direct vasodilatory effects counteracting the
reduced levels of vasodilating prostacyclin remain to be
investigated.
FIGURE 6 | PKPDmodel output. Compartmental analysis of the pharmacokinetics and urinary 6-keto-PGF1α excretion after single dose treatment with 1,000 mg
metamizole (A,B) and 500 mg naproxen (C). The model is described in the methods section and the model parameters are given in Table 3. The individual fits are
provided as supplementary material.
Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 62063511
Blaser et al. Renal Effects of Metamizole
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the Ethikkommission beider Basel, Basel,
Switzerland. The patients/participants provided their written
informed consent to participate in this study.
AUTHOR CONTRIBUTIONS
SK and MH designed study; LB, AT and EL conducted clinical
trial; LB, UD, JB and RD analysed clinical samples; JD, SK, MM
and MH analysed and interpreted data; LB and MH wrote
manuscript; all authors critically reviewed and approved the
final manuscript.
FUNDING
LSB was supported by a grant of the Senglet-Foundation, Basel,
Switzerland. SK and MH were supported by grants of the Swiss
National Science Foundation (31003A_156270 and
31003A_160206, respectively).
ACKNOWLEDGMENTS
The authors would like to thank Claudia Bläsi, Luisa Baselgia, and
Andrea Stoller for their valuable assistance during the clinical
work. The content of this manuscript has been published in part
as part of the thesis of Lea S. Blaser (Blaser, 2016).
SUPPLEMENTARY MATERIAL




Abu-Kishk, I., Goldman, M., Mordish, Y., Berkovitch, M., and Kozer, E. (2010).
Transient Renal Insufficiency Following Dipyrone Overdose. Arch. Dis. Child.
95 (3), 233–234. doi:10.1136/adc.2009.171793
Anastasio, P., Cirillo, M., Spitali, L., Frangiosa, A., Pollastro, R. M., and De Santo,
N. G. (2001). Level of Hydration and Renal Function in Healthy Humans.
Kidney Int. 60 (2), 748–756. doi:10.1046/j.1523-1755.2001.060002748.x
Andrade, S., Bartels, D. B., Lange, R., Sandford, L., and Gurwitz, J. (2016). Safety of
Metamizole: a Systematic Review of the Literature. J. Clin. Pharm. Ther. 41 (5),
459–477. doi:10.1111/jcpt.12422
Anonymous (1986). Risks of Agranulocytosis and Aplastic Anemia. A First Report
of Their Relation to Drug Use with Special Reference to Analgesics. The
International Agranulocytosis and Aplastic Anemia Study. JAMA 256 (13),
1749–1757. doi:10.1001/jama.1986.03380130077032
Berruti, V., Salvidio, G., Saffioti, S., Pontremoli, R., Arnone, O., Giannoni, M., et al.
(1998). Noramidopyrine (Metamizol) and Acute Interstitial Nephritis.Nephrol.
Dial. Transpl. 13 (8), 2110–2112. doi:10.1093/ndt/13.8.2110
Bhala, N., Emberson, J., Merhi, A., Abramson, S., and Arber, N. Coxib (2013).
Vascular and Upper Gastrointestinal Effects of Non-steroidal Anti-
inflammatory Drugs: Meta-Analyses of Individual Participant Data from
Randomised Trials. Lancet 382 (9894), 769–779. doi:10.1016/S0140-6736(13)
60900-9
Blaser, L. S. (2016). Clinical Safety of Metamizole (Dissertation). Switzerland:
University of Basel.
Blatnik, M., and Steenwyk, R. C. (2010). Quantification of Urinary PGEm, 6-keto
PGF(1alpha) and 2,3-Dinor-6-Keto PGF(1alpha) by UFLC-MS/MS before and
after Exercise. Prostaglandins Other Lipid Mediat 93 (1-2), 8–13. doi:10.1016/
j.prostaglandins.2010.04.002
Campos, C., de Gregorio, R., García-Nieto, R., Gago, F., Ortiz, P., and Alemany, S.
(1999). Regulation of Cyclooxygenase Activity byMetamizol. Eur. J. Pharmacol.
378 (3), 339–347. doi:10.1016/s0014-2999(99)00477-x
Crunfli, F., Vilela, F. C., and Giusti-Paiva, A. (2015). Cannabinoid CB1 Receptors
Mediate the Effects of Dipyrone. Clin. Exp. Pharmacol. Physiol. 42 (3), 246–255.
doi:10.1111/1440-1681.12347
de Abajo, F. J., Gil, M. J., Bryant, V., Timoner, J., Oliva, B., and García-Rodríguez, L.
A. (2013). Upper Gastrointestinal Bleeding Associated with NSAIDs, Other
Drugs and Interactions: a Nested Case-Control Study in a New General Practice
Database. Eur. J. Clin. Pharmacol. 69 (3), 691–701. doi:10.1007/s00228-012-
1386-3
de Abajo, F. J., Gil, M. J., García Poza, P., Bryant, V., Oliva, B., Timoner, J., et al.
(2014). Risk of Nonfatal Acute Myocardial Infarction Associated with Non-
steroidal Antiinflammatory Drugs, Non-narcotic Analgesics and Other Drugs
Used in Osteoarthritis: a Nested Case-Control Study. Pharmacoepidemiol. Drug
Saf. 23 (11), 1128–1138. doi:10.1002/pds.3617
Dilger, K., Herrlinger, C., Peters, J., Seyberth, H. W., Schweer, H., and Klotz, U.
(2002). Effects of Celecoxib and Diclofenac on Blood Pressure, Renal Function,
and Vasoactive Prostanoids in Young and Elderly Subjects. J. Clin. Pharmacol.
42 (9), 985–994. doi:10.1177/0091270002042009005
Elia, C., Graupera, I., Barreto, R., Solà, E., Moreira, R., Huelin, P., et al. (2015).
Severe Acute Kidney Injury Associated with Non-steroidal Anti-inflammatory
Drugs in Cirrhosis: A Case-Control Study. J. Hepatol. 63 (3), 593–600.
doi:10.1016/j.jhep.2015.04.004
Ergün, H., Ayhan, I. H., and Tulunay, F. C. (1999). Pharmacological
Characterization of Metamizol-Induced Relaxation in Phenylephrine-
Precontracted Rabbit Thoracic Aorta Smooth Muscle. Gen. Pharmacol. 33
(3), 237–241. doi:10.1016/s0306-3623(99)00013-0
Ergün, H., Bağdatoğlu, C., Uğur, H. C., Temiz, C., Attar, A., Egemen, N., et al.
(2000). The Vasorelaxant Effect of Dipyrone on an Experimental Cerebral
Vasospasm Model in Rabbits. Neurol. Res. 22 (8), 815–818. doi:10.1080/
01616412.2000.11740758
Eriksson, L. O., Sturfelt, G., Thysell, H., and Wollheim, F. A. (1990). Effects of
Sulindac and Naproxen on Prostaglandin Excretion in Patients with Impaired
Renal Function and Rheumatoid Arthritis. Am. J. Med. 89 (3), 313–321.
doi:10.1016/0002-9343(90)90344-d
Farker, K., Merkel, U., Schweer, H., Haerting, J., Madani, S. F., Eggers, R., et al.
(2002). Effects of Short-Term Treatment with Diclofenac-Colestyramine on
Renal Function and Urinary Prostanoid Excretion in Patients with Type-2
Diabetes. Eur. J. Clin. Pharmacol. 58 (2), 85–91. doi:10.1007/s00228-002-
0440-y
Farker, K., Nassr, N., Huck, F., Zerle, G., Rosenkranz, B., Schmieder, G., et al.
(1995). Dipyrone and Diclofenac Do Not Influence Creatinine-Clearance,
Inulin-Clearance or PAH-Clearance in Healthy Male Volunteers. Int.
J. Clin. Pharmacol. Ther. 33 (3), 125–130.
Fosbol, E. L., Gislason, G. H., Jacobsen, S., Folke, F., Hansen, M. L., Schramm, T. K.,
et al. (2009). Risk of Myocardial Infarction and Death Associated with the Use
of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Among Healthy
Individuals: a Nationwide Cohort Study. Clin. Pharmacol. Ther. 85 (2),
190–197. doi:10.1038/clpt.2008.204
Fredman, B., Zohar, E., Golan, E., Tillinger, M., Bernheim, J., and Jedeikin, R.
(1999). Diclofenac Does Not Decrease Renal Blood Flow or Glomerular
Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 62063512
Blaser et al. Renal Effects of Metamizole
Filtration in Elderly Patients Undergoing Orthopedic Surgery. Anesth. Analg 88
(1), 149–154. doi:10.1097/00000539-199901000-00028
García Rodríguez, L. A., and Barreales Tolosa, L. (2007). Risk of Upper
Gastrointestinal Complications Among Users of Traditional NSAIDs and
COXIBs in the General Population. Gastroenterology 132 (2), 498–506.
doi:10.1053/j.gastro.2006.12.007
García Rodríguez, L. A., Lin, K. J., Hernández-Díaz, S., and Johansson, S. (2011).
Risk of Upper Gastrointestinal Bleeding with Low-Dose Acetylsalicylic Acid
Alone and in Combination with Clopidogrel and Other Medications.
Circulation 123 (10), 1108–1115. doi:10.1161/
CIRCULATIONAHA.110.973008
Gencer, A., Gunduz, O., and Ulugol, A. (2015). Involvement of Descending
Serotonergic and Noradrenergic Systems and Their Spinal Receptor
Subtypes in the Antinociceptive Effect of Dipyrone. Drug Res. (Stuttg) 65
(12), 645–649. doi:10.1055/s-0034-1398550
Gierse, J. K., Koboldt, C. M., Walker, M. C., Seibert, K., and Isakson, P. C. (1999).
Kinetic Basis for Selective Inhibition of Cyclo-Oxygenases. Biochem. J. 339 ( Pt
3) (Pt 3), 607–614. doi:10.1042/0264-6021:3390607
Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L.,
Fosbøl, E. L., et al. (2009). Increased Mortality and Cardiovascular Morbidity
Associated with Use of Nonsteroidal Anti-inflammatory Drugs in Chronic
Heart Failure. Arch. Intern. Med. 169 (2), 141–149. doi:10.1001/
archinternmed.2008.525
Gulmez, S. E., Gurdal, H., and Tulunay, F. C. (2006). Airway Smooth Muscle
Relaxations Induced by Dipyrone. Pharmacology 78 (4), 202–208. doi:10.1159/
000096688
Gülmez, S. E., Serel, S., Uluç, A., Can, Z., and Ergün, H. (2008). Dipyrone Increases
the Blood Flow of Arterial Dorsal Skin Flaps. Aesthet. Plast Surg 32 (5),
766–770. doi:10.1007/s00266-008-9126-x
Hassan, K., Khazim, K., Hassan, F., and Hassan, S. (2011). Acute Kidney Injury
Associated with Metamizole Sodium Ingestion. Ren. Fail. 33 (5), 544–547.
doi:10.3109/0886022X.2011.569107
Hinz, B., Cheremina, O., Bachmakov, J., Renner, B., Zolk, O., Fromm, M. F., et al.
(2007). Dipyrone Elicits Substantial Inhibition of Peripheral Cyclooxygenases
in Humans: New Insights into the Pharmacology of an Old Analgesic. FASEB J.
21 (10), 2343–2351. doi:10.1096/fj.06-8061com
Hörl, W. H. (2010). Nonsteroidal Anti-inflammatory Drugs and the Kidney.
Pharmaceuticals (Basel) 3 (7), 2291–2321. doi:10.3390/ph3072291
Huledal, G., Jonzon, B., Malmenäs, M., Hedman, A., Andersson, L. I., Odlind, B.,
et al. (2005). Renal Effects of the Cyclooxygenase-Inhibiting Nitric Oxide
Donator AZD3582 Compared with Rofecoxib and Naproxen during normal
and Low Sodium Intake. Clin. Pharmacol. Ther. 77 (5), 437–450. doi:10.1016/
j.clpt.2005.01.011
Imani, F., Motavaf, M., Safari, S., and Alavian, S. M. (2014). The Therapeutic Use of
Analgesics in Patients with Liver Cirrhosis: a Literature Review and Evidence-
Based Recommendations. Hepat. Mon 14 (10), e23539. doi:10.5812/
hepatmon.23539
Kamper, A. L., Strandgaard, S., Christensen, P., and Svendsen, U. G. (1986). Effects
of Sulindac and Naproxen in Patients with Chronic Glomerular Disease. Scand.
J. Rheumatol. Suppl. 62, 26–31. doi:10.3109/03009748609101451
Kinn, A. C., Elbarouni, J., Seideman, P., and Sollevi, A. (1989). The Effect of
Diclofenac Sodium on Renal Function. Scand. J. Urol. Nephrol. 23 (2), 153–157.
doi:10.3109/00365598909180832
Kuehnle, H. F., von Dahl, K., and Schmidt, F. H. (1992). Fully Enzymatic Inulin
Determination in Small Volume Samples without Deproteinization. Nephron
62 (1), 104–107. doi:10.1159/000187006
Lanas, A., Serrano, P., Bajador, E., Fuentes, J., and Sáinz, R. (2003). Risk of Upper
Gastrointestinal Bleeding Associated with Non-aspirin Cardiovascular Drugs,
Analgesics and Nonsteroidal Anti-inflammatory Drugs. Eur. J. Gastroenterol.
Hepatol. 15 (2), 173–178. doi:10.1097/00042737-200302000-00011
LaporteCarne, J. R., Carné, X., Vidal, X., Moreno, V., and Juan, J. (1991). Upper
Gastrointestinal Bleeding in Relation to Previous Use of Analgesics and Non-
steroidal Anti-inflammatory Drugs. Catalan Countries Study on Upper
Gastrointestinal Bleeding. Lancet 337 (8733), 85–89. doi:10.1016/0140-
6736(91)90744-a
Leone, R., Conforti, A., Venegoni, M., Motola, D., Moretti, U., Meneghelli, I., et al.
(2005). Drug-induced Anaphylaxis : Case/non-Case Study Based on an Italian
Pharmacovigilance Database.Drug Saf. 28 (6), 547–556. doi:10.2165/00002018-
200528060-00006
Levy, M., Zylber-Katz, E., and Rosenkranz, B. (1995). Clinical Pharmacokinetics of
Dipyrone and its Metabolites. Clin. Pharmacokinet. 28 (3), 216–234.
doi:10.2165/00003088-199528030-00004
Muther, R. S., Potter, D. M., and Bennett, W. M. (1981). Aspirin-induced
Depression of Glomerular Filtration Rate in normal Humans: Role of
Sodium Balance. Ann. Intern. Med. 94 (3), 317–321. doi:10.7326/0003-4819-
94-3-317
Nassini, R., Fusi, C., Materazzi, S., Coppi, E., Tuccinardi, T., Marone, I. M., et al.
(2015). The TRPA1 Channel Mediates the Analgesic Action of Dipyrone and
Pyrazolone Derivatives. Br. J. Pharmacol. 172 (13), 3397–3411. doi:10.1111/
bph.13129
Novalgin, P. I. (2015). Product Information Novalgin Swissmedic 2015. Available
from: http://www.swissmedicinfo.ch (accessed 10 08, 2015).[
Pierre, S. C., Schmidt, R., Brenneis, C., Michaelis, M., Geisslinger, G., and Scholich,
K. (2007). Inhibition of Cyclooxygenases by Dipyrone. Br. J. Pharmacol. 151 (4),
494–503. doi:10.1038/sj.bjp.0707239
Rogosch, T., Sinning, C., Podlewski, A., Watzer, B., Schlosburg, J., Lichtman,
A. H., et al. (2012). Novel Bioactive Metabolites of Dipyrone
(Metamizol). Bioorg. Med. Chem. 20 (1), 101–107. doi:10.1016/
j.bmc.2011.11.028
Rosenkranz, B., Lehr, K. H., Mackert, G., and Seyberth, H. W. (1992). Metamizole-
furosemide Interaction Study in Healthy Volunteers. Eur. J. Clin. Pharmacol. 42
(6), 593–598. doi:10.1007/BF00265921
Rossat, J., Maillard, M., Nussberger, J., Brunner, H. R., and Burnier, M. (1999).
Renal Effects of Selective Cyclooxygenase-2 Inhibition in Normotensive Salt-
Depleted Subjects. Clin. Pharmacol. Ther. 66 (1), 76–84. doi:10.1016/S0009-
9236(99)70056-1
Sánchez, S., Alarcón de la Lastra, C., Ortiz, P., Motilva, V., andMartín, M. J. (2002).
Gastrointestinal Tolerability of Metamizol, Acetaminophen, and Diclofenac in
Subchronic Treatment in Rats. Dig. Dis. Sci. 47 (12), 2791–2798. doi:10.1023/a:
1021077810548
Sánchez, S., Alarcón de la Lastra, C., Ortiz, P., Motilva, V., andMartín, M. J. (2002).
Gastrointestinal Tolerability of Metamizol, Acetaminophen, and Diclofenac in
Subchronic Treatment in Rats. Dig. Dis. Sci. 47 (12), 2791–2798. doi:10.1023/a:
1021077810548
Scarpignato, C., Lanas, A., Blandizzi, C., Lems, W. F., Hermann, M., Hunt, R. H.,
et al. (2015). Safe Prescribing of Non-steroidal Anti-inflammatory Drugs in
Patients with Osteoarthritis-Aan Expert Consensus Addressing Benefits asWell
as Gastrointestinal and Cardiovascular Risks. BMC Med. 13, 55. doi:10.1186/
s12916-015-0285-8
Siebel, J. S., Beirith, A., and Calixto, J. B. (2004). Evidence for the Involvement of
Metabotropic Glutamatergic, Neurokinin 1 Receptor Pathways and Protein
Kinase C in the Antinociceptive Effect of Dipyrone in Mice. Brain Res. 1003 (1-
2), 61–67. doi:10.1016/j.brainres.2003.11.075
Silav, G., Ergün, H., Dolgun, H., Sancak, T., Sargon, M. F., and Egemen, N. (2017).
Dipyrone Attenuates Cerebral Vasospasm after Experimental Subarachnoid
Hemorrhage in Rabbits. J. Neurosurg. Sci. 61 (4), 380–387. doi:10.23736/S0390-
5616.16.03068-X
Stammschulte, T., Ludwig, W. D., Mühlbauer, B., Bronder, E., and Gundert-Remy,
U. (2015). Metamizole (Dipyrone)-associated Agranulocytosis. An Analysis of
German Spontaneous Reports 1990-2012. Eur. J. Clin. Pharmacol. 71 (9),
1129–1138. doi:10.1007/s00228-015-1895-y
Sterz, K., Scherer, G., and Ecker, J. (2012). A Simple and Robust UPLC-SRM/MS
Method to Quantify Urinary Eicosanoids. J. Lipid Res. 53 (5), 1026–1036.
doi:10.1194/jlr.D023739
Valenzuela, F., García-Saisó, S., Lemini, C., Ramírez-Solares, R., Vidrio, H.,
and Mendoza-Fernández, V. (2005). Metamizol Acts as an ATP Sensitive
Potassium Channel Opener to Inhibit the Contracting Response Induced
by Angiotensin II but Not to Norepinephrine in Rat Thoracic Aorta
Smooth Muscle. Vascul Pharmacol. 43 (2), 120–127. doi:10.1016/
j.vph.2005.05.003
van Acker, B. A., Koomen, G. C., Koopman, M. G., de Waart, D. R., and Arisz, L.
(1992). Creatinine Clearance during Cimetidine Administration for
Measurement of Glomerular Filtration Rate. Lancet 340 (8831), 1326–1329.
doi:10.1016/0140-6736(92)92502-7
Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 62063513
Blaser et al. Renal Effects of Metamizole
Whelton, A., Lefkowith, J. L., West, C. R., and Verburg, K. M. (2006). Cardiorenal
Effects of Celecoxib as Compared with the Nonsteroidal Anti-inflammatory
Drugs Diclofenac and Ibuprofen. Kidney Int. 70 (8), 1495–1502. doi:10.1038/
sj.ki.5001766
Wouda, R. D., Dekker, S. E. I., Reijm, J., Olde Engberink, R. H. G., and Vogt, L.
(2019). Effects of Water Loading on Observed and Predicted
Plasma Sodium, and Fluid and Urine Cation Excretion in Healthy
Individuals. Am. J. Kidney Dis. 74 (3), 320–327. doi:10.1053/
j.ajkd.2019.02.021
Zapater, P., Llanos, L., Barquero, C., Bellot, P., Pascual, S., Carnicer, F., et al. (2015).
Acute Effects of Dipyrone on Renal Function in Patients with Cirrhosis: a
Randomized Controlled Trial. Basic Clin. Pharmacol. Toxicol. 116 (3), 257–263.
doi:10.1111/bcpt.12312
Zhang, Y., Huo, M., Zhou, J., and Xie, S. (2010). PKSolver: An Add-In Program for
Pharmacokinetic and Pharmacodynamic Data Analysis in Microsoft Excel.
Comput. Methods Programs Biomed. 99 (3), 306–314. doi:10.1016/
j.cmpb.2010.01.007
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Blaser, Duthaler, Bouitbir, Leuppi-Taegtmeyer, Liakoni, Dolf,
Mayr, Drewe, Krähenbühl and Haschke. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 62063514
Blaser et al. Renal Effects of Metamizole
